EP2109687A4 - Micro-rna-based methods and compositions for the treatment of acute myeloid leukemia - Google Patents

Micro-rna-based methods and compositions for the treatment of acute myeloid leukemia

Info

Publication number: EP2109687A4
Authority: EP; European Patent Office
Prior art keywords: rna; micro; compositions; treatment; myeloid leukemia
Prior art date: 2007-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP08713330A

Other languages

German (de)

French (fr)

Other versions

EP2109687A2 (en

EP2109687B1 (en

Inventor

Carlo M Croce

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ohio State University Research Foundation

Original Assignee

Ohio State University Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-31

Filing date

2008-01-29

Publication date

2011-08-24

2008-01-29 Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation

2009-10-21 Publication of EP2109687A2 publication Critical patent/EP2109687A2/en

2011-08-24 Publication of EP2109687A4 publication Critical patent/EP2109687A4/en

2014-06-04 Application granted granted Critical

2014-06-04 Publication of EP2109687B1 publication Critical patent/EP2109687B1/en

Status Not-in-force legal-status Critical Current

2028-01-29 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Pathology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP20080713330 2007-01-31 2008-01-29 Micro-rna-based methods for the treatment of acute myeloid leukemia Not-in-force EP2109687B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89857807P	2007-01-31	2007-01-31
PCT/US2008/001157 WO2008094545A2 (en)	2007-01-31	2008-01-29	Mic orna-based methods and compositions for the treatment of acute myeloid leukemia

Publications (3)

Publication Number	Publication Date
EP2109687A2 EP2109687A2 (en)	2009-10-21
EP2109687A4 true EP2109687A4 (en)	2011-08-24
EP2109687B1 EP2109687B1 (en)	2014-06-04

Family

ID=39674697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP20080713330 Not-in-force EP2109687B1 (en)	2007-01-31	2008-01-29	Micro-rna-based methods for the treatment of acute myeloid leukemia

Country Status (7)

Country	Link
US (4)	US8034560B2 (en)
EP (1)	EP2109687B1 (en)
JP (1)	JP2010516291A (en)
CN (3)	CN101627134B (en)
AU (1)	AU2008211142A1 (en)
CA (1)	CA2674895A1 (en)
WO (1)	WO2008094545A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105902559A (en)	2005-08-01	2016-08-31	俄亥俄州立大学研究基金会	Diagnosis and prognosis for breast cancer, micro RNA-based method and micro RNA-based composition for treating breast cancer
AU2006291165B2 (en) *	2005-09-12	2013-03-14	The Ohio State University Research Foundation	Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
CN101312740A (en) *	2005-10-05	2008-11-26	俄亥俄州立大学研究基金会	Wwox gene, vectors containing the same, and uses in treatment of cancer
US7943318B2 (en)	2006-01-05	2011-05-17	The Ohio State University Research Foundation	Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP1968622B1 (en)	2006-01-05	2014-08-27	The Ohio State University Research Foundation	Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2526787T3 (en)	2006-01-05	2015-01-15	The Ohio State University Research Foundation	MicroRNA based methods for the diagnosis of colon, pancreas and stomach cancers
EP2371971B1 (en)	2006-03-20	2013-11-27	The Ohio State University Research Foundation	Microrna fingerprints during human megakaryocytopoiesis
ES2434090T3 (en)	2006-07-13	2013-12-13	The Ohio State University Research Foundation	MIR-29a for the diagnosis of colon adenocarcinoma with poor survival prognosis
US8071292B2 (en)	2006-09-19	2011-12-06	The Ohio State University Research Foundation	Leukemia diagnostic methods
ES2425416T3 (en)	2006-11-01	2013-10-15	The Ohio State University Research Foundation	Signature of microRNA expression to predict survival and metastasis in hepatocellular carcinoma
WO2008094545A2 (en) *	2007-01-31	2008-08-07	The Ohio State University Research Foundation	Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
WO2008136971A1 (en) *	2007-04-30	2008-11-13	The Ohio State University Research Foundation	Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
CN103602724B (en)	2007-06-08	2016-03-16	由卫生与公众服务部代表的美利坚合众国政府	Determine the method for hepatocellular carcinoma hypotype and detection liver-cancer stem cell
AU2008266014B2 (en)	2007-06-15	2013-06-06	The Ohio State University Research Foundation	Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
ES2496172T3 (en)	2007-07-31	2014-09-18	The Ohio State University Research Foundation	Methods to reverse methylation by targeted selection of DNMT3A and DNMT3B
EP2650383A1 (en)	2007-08-03	2013-10-16	The Ohio State University Research Foundation	Ultraconserved regions encoding ncRNAs
CA2926831A1 (en)	2007-08-22	2009-02-26	The Ohio State University Research Foundation	Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CN103937876B (en) *	2007-10-11	2016-08-17	俄亥俄州立大学研究基金会	For diagnosing and treat the method and composition of adenocarcinoma of esophagus
CN102137927B (en)	2007-10-26	2014-03-12	俄亥俄州立大学研究基金会	Methods for identifying fragile histidine triad (Fhit) interaction and uses thereof
JP2011505143A (en) *	2007-11-30	2011-02-24	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	MicroRNA expression profiling and peripheral blood targeting in lung cancer
CN102027129B (en) *	2008-02-28	2014-03-12	俄亥俄州立大学研究基金会	Microrna-based methods and compositions for diagnosis, pronosis and treatment of prostate related disorders
EP2254668A4 (en) *	2008-02-28	2012-08-15	Univ Ohio State Res Found	Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
CN102149827B (en)	2008-06-11	2014-08-20	由卫生与公众服务部代表的美利坚合众国政府	Use of MiR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
JP2012507300A (en) *	2008-10-30	2012-03-29	カリスライフサイエンシズルクセンブルクホールディングス	Method for evaluating RNA patterns
WO2010051639A1 (en) *	2008-11-10	2010-05-14	University Health Network	Use of mir-126 for enhancing hematopoietic stem cell engraftment, for isolating hematopoietic stem cells, and for treating and monitoring the treatment of acute myeloid leukemia
CN107254538A (en) *	2008-11-12	2017-10-17	卡里斯生命科学瑞士控股有限责任公司	The method and system of phenotype is determined using allochthon
IT1398768B1 (en) *	2009-03-24	2013-03-18	Zollo	USE OF MICRORNA-199B-5P IN MEDICAL AND DIAGNOSTIC FIELD.
WO2010119698A1 (en) *	2009-04-16	2010-10-21	学校法人慶應義塾	Head-and-neck tumor proliferation inhibitor
WO2011063382A1 (en)	2009-11-23	2011-05-26	The Ohio State University	Materials and methods useful for affecting tumor cell growth, migration and invasion
AU2011219029B2 (en) *	2010-02-26	2017-02-02	Columbia University	Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
CN103237901B (en)	2010-03-01	2016-08-03	卡里斯生命科学瑞士控股有限责任公司	For treating the biomarker of diagnosis
KR20130043104A (en)	2010-04-06	2013-04-29	카리스 라이프 사이언스 룩셈부르크 홀딩스	Circulating biomarkers for disease
US10246833B2 (en) *	2017-02-23	2019-04-02	Roadtec, Inc.	Asphalt paving machine operational reporting system
EP2637673B1 (en)	2010-11-12	2016-10-26	The Ohio State University Research Foundation	Methods related to microrna-21 and mismatch repair in colorectal cancer
CA2817982C (en)	2010-11-15	2020-06-30	The Regents Of The University Of Michigan	Controlled release mucoadhesive systems
EP2683387A4 (en)	2011-03-07	2014-09-03	Univ Ohio State	MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
CN102178959B (en) *	2011-03-15	2013-10-23	清华大学深圳研究生院	siRNA for inhibiting growth of pulmonary metastasis tumor and oligonucleotide composition and application thereof
AU2012323924A1 (en)	2011-10-14	2014-05-29	The Ohio State University	Methods and materials related to ovarian cancer
JP2015501843A (en)	2011-12-13	2015-01-19	オハイオ・ステイト・イノベーション・ファウンデーション	Methods and compositions relating to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
AU2013209477B2 (en)	2012-01-20	2016-12-08	The Ohio State University	Breast cancer biomarker signatures for invasiveness and prognosis
CA2867662A1 (en) *	2012-03-21	2013-09-26	Erytech Pharma	Medicament for the treatment of acute myeloid leukemia (aml)
GB201400598D0 (en)	2014-01-14	2014-03-05	Univ Glasgow	Materials and methods for modulation of tendon healing
EP3454945B1 (en) *	2016-05-12	2022-01-19	The Regents Of The University Of Michigan	Ash1l inhibitors and methods of treatment therewith
CN105838804A (en) *	2016-05-16	2016-08-10	苏州大学	MiR-17-5p hematological malignancy auxiliary diagnosis reagent and application thereof
US10801025B2 (en)	2016-07-26	2020-10-13	Indiana University Research And Technology Corporation	MicroRNA therapy for pancreatic cancer
US20200054639A1 (en) *	2016-10-31	2020-02-20	Oregon Health & Science University	Combinations of agents to treat hematological malignancies
EP3706736A4 (en)	2017-11-10	2021-08-11	The Regents of the University of Michigan	Ash1l degraders and methods of treatment therewith
US11410745B2 (en) *	2018-06-18	2022-08-09	International Business Machines Corporation	Determining potential cancer therapeutic targets by joint modeling of survival events
CN110151777B (en) *	2019-06-03	2022-04-26	暨南大学附属第一医院（广州华侨医院）	Application of hsa-miR-12462 in resisting acute myeloid leukemia
CN113584166B (en) *	2021-07-05	2024-03-26	暨南大学	Application of miR-31-5p in acute myelogenous leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005078139A2 (en) *	2004-02-09	2005-08-25	Thomas Jefferson University	DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005118806A9 (en) *	2004-05-28	2006-02-02	Ambion Inc	METHODS AND COMPOSITIONS INVOLVING MicroRNA
FR2877350A1 (en) *	2004-11-03	2006-05-05	Centre Nat Rech Scient	IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en) *	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4172124A (en)	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
US4608337A (en) *	1980-11-07	1986-08-26	The Wistar Institute	Human hybridomas and the production of human monoclonal antibodies by human hybridomas
US4701409A (en)	1984-11-15	1987-10-20	The Wistar Institute	Detection of B-cell neoplasms
US4693975A (en)	1984-11-20	1987-09-15	The Wistar Institute	Human hybridroma fusion partner for production of human monoclonal antibodies
US5015568A (en) *	1986-07-09	1991-05-14	The Wistar Institute	Diagnostic methods for detecting lymphomas in humans
US5202429A (en) *	1986-07-09	1993-04-13	The Wistar Institute	DNA molecules having human BCL-2 gene sequences
US5198338A (en) *	1989-05-31	1993-03-30	Temple University	Molecular probing for human t-cell leukemia and lymphoma
US5149628A (en)	1989-11-15	1992-09-22	Temple University	Methods for detecting bcl-3 gene in human leukemias
US6040140A (en) *	1991-12-11	2000-03-21	Thomas Jefferson University	Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities
US5633135A (en) *	1991-12-11	1997-05-27	Thomas Jefferson University	Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities
WO1993012136A1 (en) *	1991-12-11	1993-06-24	Thomas Jefferson University	Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region
US5674682A (en) *	1992-10-29	1997-10-07	Thomas Jefferson University	Nucleic acid primers for detecting micrometastasis of prostate cancer
DK0667920T3 (en)	1992-10-29	2003-04-14	Univ Jefferson	Methods for detecting prostate cancer metastasis
US5985598A (en) *	1994-10-27	1999-11-16	Thomas Jefferson University	TCL-1 gene and protein and related methods and compositions
US7175995B1 (en) *	1994-10-27	2007-02-13	Thomas Jefferson University	TCL-1 protein and related methods
US5695944A (en)	1995-05-05	1997-12-09	Thomas Jefferson University	Modulation of bcl-2 phosphorylation
US5567586A (en)	1995-05-18	1996-10-22	Thomas Jefferson University	Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region
US5928884A (en) *	1996-02-09	1999-07-27	Croce; Carlo M.	FHIT proteins and nucleic acids and methods based thereon
US6242212B1 (en)	1996-02-09	2001-06-05	Thomas Jefferson University	Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US6187536B1 (en)	1997-02-18	2001-02-13	Thomas Jefferson University	Methods of identifying and detecting pancreatic cancer
WO1998045480A1 (en) *	1997-04-04	1998-10-15	The Texas A & M University System	Noninvasive detection of colonic biomarkers using fecal messenger rna
WO2000003685A2 (en) *	1998-07-20	2000-01-27	Thomas Jefferson University	Nitrilase homologs
US6255293B1 (en) *	1998-07-24	2001-07-03	Yeda Research And Development Co., Ltd.	Prevention of metastasis with 5-aza-2′-deoxycytidine
US7141417B1 (en)	1999-02-25	2006-11-28	Thomas Jefferson University	Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
EP1165586A4 (en)	1999-03-15	2003-05-28	Univ Jefferson	TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS
US6579857B1 (en)	1999-06-11	2003-06-17	Evanston Northwestern Healthcare Research Institute	Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US7163801B2 (en)	1999-09-01	2007-01-16	The Burnham Institute	Methods for determining the prognosis for cancer patients using tucan
US6891031B2 (en)	2000-02-18	2005-05-10	The Regents Of The University Of California	Coordinate cytokine regulatory sequences
WO2001068666A1 (en)	2000-03-14	2001-09-20	Thomas Jefferson University	Tcl1 enhances akt kinase activity and mediates its nuclear translocation
CA2406366A1 (en) *	2000-04-11	2001-10-18	Thomas Jefferson University	Muir-torre-like syndrome infhit deficient mice
US20020086331A1 (en)	2000-05-16	2002-07-04	Carlo Croce	Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers
US7060811B2 (en) *	2000-10-13	2006-06-13	Board Of Regents, The University Of Texas System	WWOX: a tumor suppressor gene mutated in multiple cancers
US20040033502A1 (en) *	2001-03-28	2004-02-19	Amanda Williams	Gene expression profiles in esophageal tissue
US20050176025A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
WO2003029459A2 (en) *	2001-09-28	2003-04-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Micro-rna molecules
US7371736B2 (en) *	2001-11-07	2008-05-13	The Board Of Trustees Of The University Of Arkansas	Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
GB0128898D0 (en) *	2001-12-03	2002-01-23	Biotech Res Ventures Pte Ltd	Materials and methods relating to the stabilization and activation of a tumour suppressor protein
RU2334744C2 (en)	2002-03-08	2008-09-27	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Macrocyclic compounds used as pharmaceutical products
AU2003226279A1 (en) *	2002-04-08	2003-10-27	Ciphergen Biosystems, Inc.	Serum biomarkers in hepatocellular carcinoma
EP1499182B1 (en) *	2002-04-29	2009-10-28	Thomas Jefferson University	Human chronic lymphocytic leukemia modeled in mouse by targeted tcl1 expression
WO2003102215A2 (en) *	2002-05-31	2003-12-11	The Board Of Trustees Of The Leland Stanford Junior University	Methods of identifying and isolating stem cells and cancer stem cells
US20050260639A1 (en)	2002-09-30	2005-11-24	Oncotherapy Science, Inc.	Method for diagnosing pancreatic cancer
WO2004033659A2 (en)	2002-10-11	2004-04-22	Thomas Jefferson University	Novel tumor suppressor gene and compositions and methods for making and using the same
US20050266443A1 (en)	2002-10-11	2005-12-01	Thomas Jefferson University	Novel tumor suppressor gene and compositions and methods for making and using the same
JP4939055B2 (en)	2002-11-13	2012-05-23	トマスジェファソンユニバーシティ	Compositions and methods for diagnosis and treatment of cancer
US7250496B2 (en)	2002-11-14	2007-07-31	Rosetta Genomics Ltd.	Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004071464A2 (en)	2003-02-12	2004-08-26	Johns Hopkins University School Of Medicine	Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
WO2004079013A1 (en)	2003-03-03	2004-09-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7183384B2 (en)	2003-03-06	2007-02-27	A & G Pharmaceutical, Inc.	Monoclonal antibody 7H11 reactive with human cancer
WO2004098377A2 (en)	2003-05-02	2004-11-18	Thomas Jefferson University	Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2006031210A1 (en) *	2003-05-29	2006-03-23	Board Of Regents, The University Of Texas Systems	Jabi as a prognostic marker and a therapeutic target for human cancer
ATE420160T1 (en)	2003-06-18	2009-01-15	Genelux Corp	MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8106180B2 (en)	2003-08-07	2012-01-31	Whitehead Institute For Biomedical Research	Methods and products for expression of micro RNAs
US20050037362A1 (en) *	2003-08-11	2005-02-17	Eppendorf Array Technologies, S.A.	Detection and quantification of siRNA on microarrays
US8412541B2 (en)	2003-08-14	2013-04-02	Edda Technology, Inc.	Method and system for intelligent qualitative and quantitative analysis for medical diagnosis
WO2005020795A2 (en)	2003-08-25	2005-03-10	The Johns Hopkins University	Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis
CN1882702A (en) *	2003-09-22	2006-12-20	罗斯塔英法美蒂克斯有限责任公司	Synthetic lethal screen using RNA interference
AU2004276823A1 (en) *	2003-09-22	2005-04-07	Merck And Co., Inc	Synthetic lethal screen using RNA interference
EP1668155A2 (en) *	2003-09-24	2006-06-14	Oncotherapy Science, Inc.	Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
US20050186589A1 (en) *	2003-11-07	2005-08-25	University Of Massachusetts	Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi
US20050164252A1 (en)	2003-12-04	2005-07-28	Yeung Wah Hin A.	Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell
JP2007514442A (en)	2003-12-19	2007-06-07	ザリージェンツオブザユニバーシティオブカリフォルニア	Methods and materials for evaluating prostate cancer treatment
JP4120002B2 (en) *	2004-01-07	2008-07-16	愛知県	Cancer prognosis determination method using miRNA, cancer gene therapy vector, and cancer therapeutic pharmaceutical composition
WO2005078096A2 (en)	2004-02-09	2005-08-25	University Of Massachusetts	Dual functional oligonucleotides for use in repressing mutant gene expression
US7772389B2 (en)	2004-02-13	2010-08-10	Rockefeller University	Anti-microRNA oligonucleotide molecules
JP4980878B2 (en)	2004-02-23	2012-07-18	エラスムスユニバーシティメディカルセンターロッテルダム	Classification, diagnosis, and prognosis of acute myeloid leukemia by gene expression profiling
US7365058B2 (en)	2004-04-13	2008-04-29	The Rockefeller University	MicroRNA and methods for inhibiting same
BRPI0509979A (en)	2004-04-20	2007-10-16	Genaco Biomedical Products Inc	method to detect ncrna
AU2005243410B2 (en) *	2004-05-14	2010-04-22	Rosetta Genomics Ltd.	Micronas and uses thereof
US7635563B2 (en) *	2004-06-30	2009-12-22	Massachusetts Institute Of Technology	High throughput methods relating to microRNA expression analysis
US20060037088A1 (en) *	2004-08-13	2006-02-16	Shulin Li	Gene expression levels as predictors of chemoradiation response of cancer
JP2008511678A (en)	2004-09-02	2008-04-17	イェールユニバーシティ	Regulation of oncogene by microRNA
US7592441B2 (en)	2004-10-04	2009-09-22	Rosetta Genomics Ltd	Liver cancer-related nucleic acids
US7642348B2 (en) *	2004-10-04	2010-01-05	Rosetta Genomics Ltd	Prostate cancer-related nucleic acids
EP2322616A1 (en)	2004-11-12	2011-05-18	Asuragen, Inc.	Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2008073922A2 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	Functions and targets of let-7 micro rnas
AU2005316384B2 (en) *	2004-12-14	2012-02-09	Alnylam Pharmaceuticals, Inc.	RNAi modulation of MLL-AF4 and uses thereof
BRPI0515794A (en) *	2004-12-17	2008-08-05	Veridex Llc	processes to evaluate patients with acute myeloid leukemia
US20060185027A1 (en)	2004-12-23	2006-08-17	David Bartel	Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1838870A2 (en) *	2004-12-29	2007-10-03	Exiqon A/S	NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US20090123912A1 (en) *	2005-01-25	2009-05-14	Rosetta Inpharmatics Llc	Methods for quantitating small RNA molecules
US8071306B2 (en)	2005-01-25	2011-12-06	Merck Sharp & Dohme Corp.	Methods for quantitating small RNA molecules
US20070065840A1 (en) *	2005-03-23	2007-03-22	Irena Naguibneva	Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
GB2425311A (en)	2005-04-15	2006-10-25	Ist Superiore Sanita	Micro RNA against kit protein
EP2631293A3 (en)	2005-04-29	2013-11-20	The Rockefeller University	Human microRNAs and methods for inhibiting same
WO2006133022A2 (en)	2005-06-03	2006-12-14	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070065844A1 (en) *	2005-06-08	2007-03-22	Massachusetts Institute Of Technology	Solution-based methods for RNA expression profiling
US20060292616A1 (en)	2005-06-23	2006-12-28	U.S. Genomics, Inc.	Single molecule miRNA-based disease diagnostic methods
CN105902559A (en)	2005-08-01	2016-08-31	俄亥俄州立大学研究基金会	Diagnosis and prognosis for breast cancer, micro RNA-based method and micro RNA-based composition for treating breast cancer
US20070213292A1 (en)	2005-08-10	2007-09-13	The Rockefeller University	Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CA2618995A1 (en) *	2005-08-10	2007-02-22	The Rockefeller University	Antagomirs for use in inhibiting mir-122
AU2006291165B2 (en)	2005-09-12	2013-03-14	The Ohio State University Research Foundation	Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
CN101312740A (en)	2005-10-05	2008-11-26	俄亥俄州立大学研究基金会	Wwox gene, vectors containing the same, and uses in treatment of cancer
US7390792B2 (en) *	2005-12-15	2008-06-24	Board Of Regents, The University Of Texas System	MicroRNA1 therapies
EP1968622B1 (en)	2006-01-05	2014-08-27	The Ohio State University Research Foundation	Microrna expression abnormalities in pancreatic endocrine and acinar tumors
US7943318B2 (en)	2006-01-05	2011-05-17	The Ohio State University Research Foundation	Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2526787T3 (en)	2006-01-05	2015-01-15	The Ohio State University Research Foundation	MicroRNA based methods for the diagnosis of colon, pancreas and stomach cancers
CA2636990A1 (en)	2006-01-13	2007-07-26	Battelle Memorial Institute	Animal model for assessing copd-related diseases
EP2371971B1 (en)	2006-03-20	2013-11-27	The Ohio State University Research Foundation	Microrna fingerprints during human megakaryocytopoiesis
US20090324618A1 (en)	2006-03-24	2009-12-31	Armstrong Scott A	Novel signature self renewal gene expression programs
WO2007112753A2 (en)	2006-04-03	2007-10-11	Santaris Pharma A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2023944A4 (en) *	2006-04-24	2011-10-05	Univ Ohio State Res Found	Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice
ES2434090T3 (en)	2006-07-13	2013-12-13	The Ohio State University Research Foundation	MIR-29a for the diagnosis of colon adenocarcinoma with poor survival prognosis
CN101528223B (en)	2006-08-30	2013-05-01	密执安州立大学董事会	New small molecule inhibitors of MDM2 and the uses thereof
US20080193943A1 (en)	2006-09-05	2008-08-14	Abbott Laboratories	Companion diagnostic assays for cancer therapy
AU2007299748A1 (en)	2006-09-19	2008-03-27	Asuragen, Inc.	miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
US8071292B2 (en) *	2006-09-19	2011-12-06	The Ohio State University Research Foundation	Leukemia diagnostic methods
WO2008036741A2 (en) *	2006-09-19	2008-03-27	Asuragen, Inc.	Mir-200 regulated genes and pathways as targets for therapeutic intervention
CA2664383C (en) *	2006-09-19	2017-08-22	Asuragen, Inc.	Micrornas differentially expressed in pancreatic diseases and uses thereof
ES2425416T3 (en) *	2006-11-01	2013-10-15	The Ohio State University Research Foundation	Signature of microRNA expression to predict survival and metastasis in hepatocellular carcinoma
US8293684B2 (en) *	2006-11-29	2012-10-23	Exiqon	Locked nucleic acid reagents for labelling nucleic acids
WO2008070082A2 (en) *	2006-12-04	2008-06-12	The Johns Hopkins University	Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
CA2671294A1 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101622349A (en)	2006-12-08	2010-01-06	奥斯瑞根公司	miR-20 regulated genes and pathways as targets for therapeutic intervention
AU2007333106A1 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	miR-20 regulated genes and pathways as targets for therapeutic intervention
US20090175827A1 (en) *	2006-12-29	2009-07-09	Byrom Mike W	miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008094545A2 (en)	2007-01-31	2008-08-07	The Ohio State University Research Foundation	Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
US8765702B2 (en)	2007-02-27	2014-07-01	Rosetta Genomics Ltd.	Composition and methods for modulating cell proliferation and cell death
JP5331714B2 (en)	2007-03-16	2013-10-30	コヴァルクス・アーゲー	Direct mass spectrometry of drug candidates targeting protein complexes
EP2134874A4 (en)	2007-04-10	2010-12-22	Univ Nat Taiwan	Predicting post-treatment survival in cancer patients with micrornas
WO2008136971A1 (en)	2007-04-30	2008-11-13	The Ohio State University Research Foundation	Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
US20090005336A1 (en) *	2007-05-08	2009-01-01	Zhiguo Wang	Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
US20090232893A1 (en)	2007-05-22	2009-09-17	Bader Andreas G	miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) *	2007-05-22	2009-05-21	Bader Andreas G	miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008154098A2 (en) *	2007-06-07	2008-12-18	Wisconsin Alumni Research Foundation	Reagents and methods for mirna expression analysis and identification of cancer biomarkers
CN103602724B (en)	2007-06-08	2016-03-16	由卫生与公众服务部代表的美利坚合众国政府	Determine the method for hepatocellular carcinoma hypotype and detection liver-cancer stem cell
EP2167138A2 (en)	2007-06-08	2010-03-31	Asuragen, INC.	Mir-34 regulated genes and pathways as targets for therapeutic intervention
AU2008266014B2 (en) *	2007-06-15	2013-06-06	The Ohio State University Research Foundation	Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
ES2496172T3 (en)	2007-07-31	2014-09-18	The Ohio State University Research Foundation	Methods to reverse methylation by targeted selection of DNMT3A and DNMT3B
EP2650383A1 (en)	2007-08-03	2013-10-16	The Ohio State University Research Foundation	Ultraconserved regions encoding ncRNAs
CA2926831A1 (en)	2007-08-22	2009-02-26	The Ohio State University Research Foundation	Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
US20090061424A1 (en) *	2007-08-30	2009-03-05	Sigma-Aldrich Company	Universal ligation array for analyzing gene expression or genomic variations
AU2008296022B2 (en)	2007-09-06	2014-01-23	The Ohio State University Research Foundation	MicroRNA signatures in human ovarian cancer
CN103937876B (en)	2007-10-11	2016-08-17	俄亥俄州立大学研究基金会	For diagnosing and treat the method and composition of adenocarcinoma of esophagus
CN102137927B (en)	2007-10-26	2014-03-12	俄亥俄州立大学研究基金会	Methods for identifying fragile histidine triad (Fhit) interaction and uses thereof
EP2217706B1 (en)	2007-11-12	2015-05-27	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US20090123933A1 (en) *	2007-11-12	2009-05-14	Wake Forest University Health Sciences	Microrna biomarkers in lupus
JP2011505143A (en)	2007-11-30	2011-02-24	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	MicroRNA expression profiling and peripheral blood targeting in lung cancer
US8071562B2 (en) *	2007-12-01	2011-12-06	Mirna Therapeutics, Inc.	MiR-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) *	2007-12-21	2009-07-09	Asuragen, Inc.	Mir-10 regulated genes and pathways as targets for therapeutic intervention
SG10201609507TA (en)	2008-02-01	2017-01-27	Gen Hospital Corp	Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
EP2260110B1 (en)	2008-02-08	2014-11-12	Asuragen, INC.	miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
CN102027129B (en)	2008-02-28	2014-03-12	俄亥俄州立大学研究基金会	Microrna-based methods and compositions for diagnosis, pronosis and treatment of prostate related disorders
AU2009219190A1 (en)	2008-02-28	2009-09-03	The Ohio State University Research Foundation	MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
EP2254668A4 (en)	2008-02-28	2012-08-15	Univ Ohio State Res Found	Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
AU2009219203B2 (en)	2008-02-28	2014-04-03	The Ohio State University Research Foundation	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia (AML) and uses thereof
EP2268832A2 (en)	2008-03-06	2011-01-05	Asuragen, INC.	Microrna markers for recurrence of colorectal cancer
WO2009154835A2 (en)	2008-03-26	2009-12-23	Asuragen, Inc.	Compositions and methods related to mir-16 and therapy of prostate cancer
US8258111B2 (en)	2008-05-08	2012-09-04	The Johns Hopkins University	Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8900627B2 (en)	2008-06-06	2014-12-02	Mirna Therapeutics, Inc.	Compositions for the in vivo delivery of RNAi agents
CN102149827B (en)	2008-06-11	2014-08-20	由卫生与公众服务部代表的美利坚合众国政府	Use of MiR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
AU2009281969A1 (en)	2008-08-12	2010-02-18	The Ohio State University Research Foundation	Micro-RNA-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
JP2012509886A (en)	2008-11-21	2012-04-26	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	Tcl1 as a transcriptional regulator
JP2012510813A (en)	2008-12-05	2012-05-17	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	MicroRNA-based methods and compositions for diagnosis and treatment of ovarian cancer
US20120027753A1 (en)	2009-02-26	2012-02-02	The Ohio State University	MicroRNAs in Never-Smokers and Related Materials and Methods

2008
- 2008-01-29 WO PCT/US2008/001157 patent/WO2008094545A2/en active Application Filing
- 2008-01-29 CN CN2008800037367A patent/CN101627134B/en not_active Expired - Fee Related
- 2008-01-29 CN CN201510615615.XA patent/CN105256004A/en active Pending
- 2008-01-29 US US12/523,915 patent/US8034560B2/en active Active
- 2008-01-29 CA CA 2674895 patent/CA2674895A1/en not_active Abandoned
- 2008-01-29 JP JP2009548281A patent/JP2010516291A/en active Pending
- 2008-01-29 AU AU2008211142A patent/AU2008211142A1/en not_active Abandoned
- 2008-01-29 CN CN201310439889.9A patent/CN103555825B/en not_active Expired - Fee Related
- 2008-01-29 EP EP20080713330 patent/EP2109687B1/en not_active Not-in-force
2011
- 2011-10-07 US US13/269,410 patent/US8354229B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,404 patent/US8530159B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,407 patent/US8431342B2/en not_active Expired - Fee Related

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005078139A2 (en) *	2004-02-09	2005-08-25	Thomas Jefferson University	DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005118806A9 (en) *	2004-05-28	2006-02-02	Ambion Inc	METHODS AND COMPOSITIONS INVOLVING MicroRNA
FR2877350A1 (en) *	2004-11-03	2006-05-05	Centre Nat Rech Scient	IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARZON RAMIRO ET AL: "JicroRNA fingerprints during human megakaryocytopoiesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 103, no. 13, 28 March 2006 (2006-03-28), pages 5078 - 5083, XP002465978, ISSN: 0027-8424, DOI: 10.1073/PNAS.0600587103 *
GARZON RAMIRO ET AL: "MicroRNA signatures associated with cytogenetics and outcome in acute myeloid leukemia", BLOOD, & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, vol. 108, no. 11, Part 1, 1 November 2006 (2006-11-01), pages 49A, XP002485554 *
LU JUN ET AL: "MicroRNA expression profiles classify human cancers", NATURE, NATURE PUBLISHING GROUP, GB, vol. 435, no. 7043, 9 June 2005 (2005-06-09), pages 834 - 838, XP002485555, DOI: 10.1038/NATURE03702 *
S DEBERNARDI ET AL: "MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis", LEUKEMIA, 1 March 2007 (2007-03-01), XP055001399, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2404605 *

Also Published As

Publication number	Publication date
WO2008094545A3 (en)	2008-12-04
US20100048681A1 (en)	2010-02-25
EP2109687A2 (en)	2009-10-21
CN101627134B (en)	2013-11-06
US20120028831A1 (en)	2012-02-02
CN103555825B (en)	2015-09-30
WO2008094545A2 (en)	2008-08-07
US20120028832A1 (en)	2012-02-02
CA2674895A1 (en)	2008-08-07
US8354229B2 (en)	2013-01-15
AU2008211142A1 (en)	2008-08-07
US8034560B2 (en)	2011-10-11
CN105256004A (en)	2016-01-20
CN101627134A (en)	2010-01-13
US8530159B2 (en)	2013-09-10
US8431342B2 (en)	2013-04-30
US20120028833A1 (en)	2012-02-02
CN103555825A (en)	2014-02-05
JP2010516291A (en)	2010-05-20
EP2109687B1 (en)	2014-06-04

Publication	Publication Date	Title
EP2109687A4 (en)	2011-08-24	Micro-rna-based methods and compositions for the treatment of acute myeloid leukemia
IL212651A (en)	2015-03-31	Compositions for the treatment of pediatric acute lymphoblastic leukemia
HRP20160949T1 (en)	2016-10-07	Novel compositions and methods for cancer treatment
IL248204A0 (en)	2016-11-30	Combination treatment of cd38-expressing tumors
EP2361089A4 (en)	2012-08-22	Compositions and methods for the treatment of altered -synuclein function
HK1159498A1 (en)	2012-08-03	Methods and compositions for the treatment of cancer
ZA200904492B (en)	2022-03-30	Compositions and methods for the treatment of infections and tumors
EP2125855A4 (en)	2013-03-27	Methods and compositions for the treatment of cancer or other diseases
EP1969147A4 (en)	2009-11-25	Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
EP2049151A4 (en)	2010-03-24	Methods and compositions for the treatment of cancer
EP2340027A4 (en)	2012-04-04	Methods and compositions for the treatment of cancer
GB0718446D0 (en)	2007-10-31	Compositions and methods for the treatment of infection
IL205137A0 (en)	2010-11-30	5-cyanothienopyridines for the treatment of tumours
GB0909297D0 (en)	2009-07-15	Composition for the treatment of skin conditions
EP2150270A4 (en)	2011-09-28	Methods and compositions for the treatment of cancer
IL206189A0 (en)	2010-12-30	Compound for use in the treatment of cancer
EP1904088A4 (en)	2010-03-31	Compositions and methods for the treatment of cancer
IL226363A0 (en)	2013-06-27	Compounds and methods for the treatment of cancer
GB0714500D0 (en)	2007-09-05	composition and treatment
HK1209754A1 (en)	2016-04-08	Compounds and methods for the treatment of cancer
GB0808326D0 (en)	2008-06-18	Compositions and methods for the treatment of fybromyalgia
GB0602857D0 (en)	2006-03-22	The treatment of sialorrhoea
GB0719613D0 (en)	2007-11-14	The treatment of pruritis
EP2276502A4 (en)	2012-04-04	Compositions for the prevention and treatment of neuroinjury and methods of use thereof
GB0604114D0 (en)	2006-04-12	Combinations for the treatment of cancer

Legal Events

Date	Code	Title	Description
2009-09-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-10-21	17P	Request for examination filed	Effective date: 20090717
2009-10-21	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2010-05-05	DAX	Request for extension of the european patent (deleted)
2011-08-17	RIC1	Information provided on ipc code assigned before grant	Ipc: C12Q 1/68 20060101AFI20110713BHEP
2011-08-24	A4	Supplementary search report drawn up and despatched	Effective date: 20110722
2012-12-05	17Q	First examination report despatched	Effective date: 20121105
2013-07-31	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
2013-12-17	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2014-01-15	INTG	Intention to grant announced	Effective date: 20131217
2014-04-30	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2014-05-02	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2014-06-04	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2014-06-04	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2014-06-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2014-06-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 671155 Country of ref document: AT Kind code of ref document: T Effective date: 20140615
2014-07-02	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2014-07-17	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602008032565 Country of ref document: DE Effective date: 20140717
2014-10-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 671155 Country of ref document: AT Kind code of ref document: T Effective date: 20140604
2014-10-29	REG	Reference to a national code	Ref country code: NL Ref legal event code: VDEP Effective date: 20140604
2014-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140905 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140904 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2014-11-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2014-11-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2015-01-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141006
2015-02-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141004
2015-03-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602008032565 Country of ref document: DE
2015-03-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 602008032565 Country of ref document: DE Representative=s name: PATENTANWAELTE LIPPERT, STACHOW & PARTNER, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602008032565 Country of ref document: DE Representative=s name: LIPPERT STACHOW PATENTANWAELTE RECHTSANWAELTE , DE
2015-04-10	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2015-04-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2015-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2015-05-13	26N	No opposition filed	Effective date: 20150305
2015-06-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602008032565 Country of ref document: DE Effective date: 20150305
2015-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2015-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2015-08-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2015-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150129
2015-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2015-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150131
2015-11-04	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2016-01-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9
2016-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150129
2016-12-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2017-01-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10
2017-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20170125 Year of fee payment: 10 Ref country code: DE Payment date: 20170125 Year of fee payment: 10
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080129 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2017-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20170127 Year of fee payment: 10
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140604
2018-08-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602008032565 Country of ref document: DE
2018-09-26	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20180129
2018-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180131 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180801
2018-11-02	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20180928
2018-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180129